Open AccessPreclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
Author(s) -
John E. Bisi,
Jessica A. Sorrentino,
Jamie L. Jordan,
David D. Darr,
Patrick Roberts,
Francis X. Tavares,
Jay C. Strum
Publication year - 2017
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/d7wy-a980
Subject(s) - kinase , cyclin dependent kinase , cyclin , cancer research , chemistry , pharmacology , medicine , cell cycle , cancer , biochemistry